Trial reportBMC surgery2026
Investigation of oral bromelain supplementation on the healing of skin flap reconstruction after Mohs micrographic surgery (MMS) for non-melanoma skin cancers (NMSCs).
Trial report in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNon-melanoma skin cancers (NMSCs) are the most common malignancies and Mohs micrographic surgery (MMS) with flap reconstruction is the treatment of choice. This study aims to investigate the effect of bromelain on the healing of skin flaps following MMS for NMSCs.
methodsIn a single-center, parallel-group, single-blinded randomized clinical trial, 60 patients with NMSC who underwent MMS and flap reconstruction were assigned (1:1) to either an intervention group receiving bromelain (1500 mg/day, Rataheal™) for 15 days postoperatively or a control group receiving standard care alone. The primary outcome was time to suture removal; the early wound healing score (EWHS) was recorded supportively. Secondary outcomes included pain, inflammation, keloid/scar formation, cosmetic satisfaction, and traction quality.
resultsBaseline characteristics (age: 69.2 ± 13.5 years; 71.7% male; flap size: 116.1 ± 7.0 mm
conclusionBromelain supplementation is associated with earlier postoperative wound healing of skin flaps following MMS for NMSC, leading to 2.6 days earlier suture removal plus improvement in the EWHS without adverse effects. Our findings support the potential of bromelain as a safe and effective adjunct therapy for reconstructive skin cancer surgery.
trial registrationIranian Registry of Clinical Trials (IRCT20240903062943N1|| https://irct.behdasht.gov.ir/trial/79056 ), 2024.10.28, enrollment started after registration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.